UBS Maintains a 'Buy' on Cepheid (CPHD); Q2 Review

July 20, 2012 2:32 PM EDT Send to a Friend
Get Alerts CPHD Hot Sheet
Price: $38.09 -0.37%

Rating Summary:
    13 Buy, 6 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 18 | New: 13
Trade CPHD Now!
UBS maintains a 'Buy' on Cepheid (NASDAQ: CPHD) price target of $43.00 (from $45.00).

Analyst, Daniel Arias, said, "Sales of $81m (+21% y/y, -2% F/X) were $2 million below consensus, while adj EPS of $0.02 was inline, as GMs rebounded 260 bps q/q. Going foward, however, management has taken a more cautious view of the top-line & margins in 2H, which will have shares down sharply...while improving profitability clearly represents a challenge, CPHD remains a high-quality MDx asset w/ a robust (20+%) sales growth outlook & we see a rebound for shares over 3-6 months."

Arias chops FY12 EPS estimate from $0.18 to $0.02 and FY12 revenues from $342M to $335M. FY13 EPS from $0.50 to $0.23.

For an analyst ratings summary and ratings history on Cepheid click here. For more ratings news on Cepheid click here.

Shares of Cepheid closed at $43.73 yesterday, with a 52 week range of $29.71-$46.00.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

UBS

Add Your Comment